Menu
Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ
Keywords
Last Name
Institution
@uada.edu
@ualr.edu
@uapb.edu
@uark.edu
University of Arkansas for Medical Sciences
More Search Options
Announcement
You can now add alternative names!
Click here
to add other names that you've published under.
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
Overview
sponsor award id
CVL-751-PD-001
Biography
contributor
Principal Investigator
Time
start date
2020-09-10
end date
2030-08-26
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)